tSMS clinical applications

Accumulating evidence is supporting the use of tSMS as a therapeutic option for the following clinical indications.


Amyotrophic lateral sclerosis (ALS)

Our tSMS products offer a possible non-invasive disease-modifying therapy for ALS. The scientific rationale is that pathological cortical hyperexcitability contributes to the neurodegeneration of motor neurons through glutamatergic excitotoxicity. tSMS reduces cortical excitability and thus may slow down the neurodegeneration process by acting on its cause. 

Proof-of-concept of this disease-modifying effect was first provided in a pilot study suggesting that tSMS of the motor cortex for 9-18 months can modify the progression of the disease. The study was published here: 

A follow-up randomised controlled trial (NCT04393467) demonstrated that long-term, home-based, self-administered tSMS in ALS is safe and feasible. tSMS of the motor cortex did not modify disease progression during the 6 months of treatment. However, long-term follow-up revealed a substantial increase in tracheostomy free survival in patients treated with real stimulation. The results were published here: 

The clinical value of these results were remarked in the following commentary:

For more information: als@neurek.com


Parkinson's disease

A randomized controlled trial (NCT02657681) was conducted to test the hypothesis that tSMS of the motor cortex may improve levodopa-induced dyskinesias in patients with Parkinson's disease. The results demonstrated that home-based, self-administered tSMS is safe and feasible. Nine sessions of tSMS over two weeks compared to sham provided subjective benefit for the treatment of levodopa-induced dyskinesias. Objective benefit was not achieved, which should be investigated with longer tSMS treatments. The results were published here: 

For more information: pd@neurek.com


Essential tremor

A randomized double-blind pilot study (NCT03780426) was conducted to test the hypothesis that transcranial static magnetic field stimulation of the primary motor cortex  may improve tremor in patients with essential tremor. Half of the patients received one session of tSMS of the left hemisphere and the other half of the right hemisphere, with contralateral sham stimulation.

Status: completed.

For more information: et@neurek.com